Neoadjuvant Chemotherapy With PISOXO for Locally-invaded-gastric Cancer (LIGC)
Status:
Not yet recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to compare the safety and efficacy of PIPAC+SOX+OLAPARIB
for locally-invaded-gastric cancer (LIGC) patients in China. To obtain preliminary results
for designing a new phase II/III randomized controlled trial.